close

EntreMed, Inc., a clinical-stage pharmaceutical company, develops therapeutic candidates primarily for the treatment of cancer and inflammation. The company's clinical development products include ENMD-2076, an Aurora A and angiogenic kinase inhibitor with potent activity against Aurora A and multiple tyrosine kinases linked to cancer and inflammatory diseases; used to treat tumor regression in various xenograft models, such as breast, colon, and leukemia; an activity towards ex vivo-treated human leukemia patient cells; and in Phase I clinical studies to treat solid tumors and multiple myeloma. Its clinical development products also include MKC-1, an oral cell-cycle inhibitor with activity against the mTOR pathway, which is in multiple Phase II clinical trials for metastatic breast, non-small cell lung, leukemia, pancreatic, ovarian/endometrial, and solid cancer tumors; ENMD-1198, an antimitotic agent that is in Phase I studies that induces cell cycle arrest and apoptosis in tumor cells; and Panzem, a Phase I clinical trial candidate for the treatment of rheumatoid arthritis. The company has license agreements with Children's Hospital Medical Center Corporation and Celgene Corporation. EntreMed, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	2.18
Volume	43727
Volume Avg	88179
52 Week High	5.55
52 Week Low	0.90
PE	N/A
PE (group average)	39
EPS Year	-0.47
EPS change Q/Q	1000%
EPS change Q/Q Yr ago	-10.71%
EPS change Q/Q next Q est	100%
EPS change Y/Y	-7.69%
REV change Q/Q	100%
REV change Q/Q Yr ago	0%
EPS next Q est	0.00
EPS next Y est	0.00
Divident Annual	0.00
Dividend Yield	0%